Voyager Acquisition, VERAXA announce filing of Form F-4 registration statement
Business Combination Announcement: VERAXA Biotech and Voyager Acquisition Corp. have filed a registration statement for a proposed Business Combination Agreement valued at approximately $1.3 billion, where VERAXA shareholders will receive around 130 million ordinary shares of the combined entity.
Transaction Details and Timeline: The boards of both companies have unanimously approved the deal, which is expected to close in Q4 2025, pending shareholder approval and other customary conditions, with VERAXA anticipating access to up to $253 million in cash from Voyager's trust.
Trade with 70% Backtested Accuracy
Analyst Views on VACH
About VACH
About the author
Shareholder Notice: M&A Class Action Firm Ongoing Investigation into the Merger Involving PBBK, VACH, LCTC, and SMLR
Class Action Firm Recognition: Monteverde & Associates PC, led by attorney Juan Monteverde, is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report and has successfully recovered millions for shareholders.
PB Bankshares Investigation: The firm is investigating PB Bankshares Inc. regarding its sale to Norwood Financial Corp., where shareholders can choose between shares or cash, with a shareholder vote scheduled for December 10, 2025.
Other Mergers and Acquisitions: The firm is also involved in cases related to Voyager Acquisition Corp.'s merger with Veraxa Biotech AG, Lifeloc Technologies' merger with Electronic Systems Technology, and Semler Scientific's sale to Strive, Inc.
Contact Information: Shareholders with concerns or seeking more information can contact Juan Monteverde via email or phone, with services offered at no cost or obligation.
VERAXA Biotech and Voyager Acquisition Corp. Announce Filing of Form F-4 Registration Statement with the SEC
Business Combination Announcement: VERAXA Biotech AG and Voyager Acquisition Corp. have filed a registration statement with the SEC regarding their proposed business combination, which is expected to close in Q4 2025, valuing VERAXA at approximately $1.64 billion.
Transaction Details: The merger will result in existing VERAXA shareholders receiving shares in the combined company without cash proceeds, while VERAXA anticipates access to around $253 million in cash held by Voyager, subject to shareholder approvals and customary closing conditions.
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Voyager Acquisition Corp. (NASDAQ: VACH)
Class Action Firm Overview: Monteverde & Associates PC, led by attorney Juan Monteverde, is recognized as a top firm for recovering millions for shareholders and is currently investigating Voyager Acquisition Corp.'s merger with Veraxa Biotech AG.
Legal Services Offered: The firm emphasizes its successful track record in class action lawsuits and invites shareholders to contact them for free consultations regarding their concerns about the merger.
VERAXA Biotech AG to Showcase Novel Cancer Therapies at Upcoming ASCO and BIO International Conventions
Company Overview: VERAXA Biotech AG is set to showcase its innovative cancer therapies, particularly the Bi-targeted Tumor-Associated Cytotoxicity (BiTAC) platform, at the ASCO and BIO conventions while preparing for a NASDAQ listing through a merger with Voyager Acquisition Corp.
Event Participation: The company will attend the ASCO Annual Meeting from May 30 to June 3, 2025, and the BIO International Convention from June 16 to June 19, 2025, where it aims to engage potential investors and partners.
VERAXA Biotech to Attend Key Industry Conferences to Showcase BiTAC Technology Platform
VERAXA Biotech AG Announcement: VERAXA, a company focused on cancer therapies, will attend the ASCO Annual Meeting and BIO International Convention to showcase its Bi-targeted Tumor-Associated Cytotoxicity (BiTAC) platform and discuss growth plans as it prepares for a NASDAQ listing following a business combination with Voyager Acquisition Corp.
Business Combination Details: The merger with Voyager Acquisition Corp. aims to enhance VERAXA's capabilities in developing innovative oncology treatments, with both companies emphasizing their commitment to revolutionizing the healthcare sector through this partnership.
VERAXA Biotech Appoints Rick Austin as Chief Scientific Officer
New Appointment at VERAXA: VERAXA Biotech AG has appointed Dr. Rick Austin as Chief Scientific Officer, effective May 1st, to lead the advancement of their cancer therapy platform and clinical pipeline, leveraging his extensive experience in oncology drug development.
Business Combination with Voyager: VERAXA is set to become a publicly traded company through a business combination with Voyager Acquisition Corp., aiming to enhance its presence in the healthcare sector and expand its innovative therapeutic offerings.
Shareholder Notice: M&A Class Action Firm Ongoing Investigation into the Merger Involving PBBK, VACH, LCTC, and SMLR
Class Action Firm Recognition: Monteverde & Associates PC, led by attorney Juan Monteverde, is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report and has successfully recovered millions for shareholders.
PB Bankshares Investigation: The firm is investigating PB Bankshares Inc. regarding its sale to Norwood Financial Corp., where shareholders can choose between shares or cash, with a shareholder vote scheduled for December 10, 2025.
Other Mergers and Acquisitions: The firm is also involved in cases related to Voyager Acquisition Corp.'s merger with Veraxa Biotech AG, Lifeloc Technologies' merger with Electronic Systems Technology, and Semler Scientific's sale to Strive, Inc.
Contact Information: Shareholders with concerns or seeking more information can contact Juan Monteverde via email or phone, with services offered at no cost or obligation.
VERAXA Biotech and Voyager Acquisition Corp. Announce Filing of Form F-4 Registration Statement with the SEC
Business Combination Announcement: VERAXA Biotech AG and Voyager Acquisition Corp. have filed a registration statement with the SEC regarding their proposed business combination, which is expected to close in Q4 2025, valuing VERAXA at approximately $1.64 billion.
Transaction Details: The merger will result in existing VERAXA shareholders receiving shares in the combined company without cash proceeds, while VERAXA anticipates access to around $253 million in cash held by Voyager, subject to shareholder approvals and customary closing conditions.
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Voyager Acquisition Corp. (NASDAQ: VACH)
Class Action Firm Overview: Monteverde & Associates PC, led by attorney Juan Monteverde, is recognized as a top firm for recovering millions for shareholders and is currently investigating Voyager Acquisition Corp.'s merger with Veraxa Biotech AG.
Legal Services Offered: The firm emphasizes its successful track record in class action lawsuits and invites shareholders to contact them for free consultations regarding their concerns about the merger.
VERAXA Biotech AG to Showcase Novel Cancer Therapies at Upcoming ASCO and BIO International Conventions
Company Overview: VERAXA Biotech AG is set to showcase its innovative cancer therapies, particularly the Bi-targeted Tumor-Associated Cytotoxicity (BiTAC) platform, at the ASCO and BIO conventions while preparing for a NASDAQ listing through a merger with Voyager Acquisition Corp.
Event Participation: The company will attend the ASCO Annual Meeting from May 30 to June 3, 2025, and the BIO International Convention from June 16 to June 19, 2025, where it aims to engage potential investors and partners.
VERAXA Biotech to Attend Key Industry Conferences to Showcase BiTAC Technology Platform
VERAXA Biotech AG Announcement: VERAXA, a company focused on cancer therapies, will attend the ASCO Annual Meeting and BIO International Convention to showcase its Bi-targeted Tumor-Associated Cytotoxicity (BiTAC) platform and discuss growth plans as it prepares for a NASDAQ listing following a business combination with Voyager Acquisition Corp.
Business Combination Details: The merger with Voyager Acquisition Corp. aims to enhance VERAXA's capabilities in developing innovative oncology treatments, with both companies emphasizing their commitment to revolutionizing the healthcare sector through this partnership.
VERAXA Biotech Appoints Rick Austin as Chief Scientific Officer
New Appointment at VERAXA: VERAXA Biotech AG has appointed Dr. Rick Austin as Chief Scientific Officer, effective May 1st, to lead the advancement of their cancer therapy platform and clinical pipeline, leveraging his extensive experience in oncology drug development.
Business Combination with Voyager: VERAXA is set to become a publicly traded company through a business combination with Voyager Acquisition Corp., aiming to enhance its presence in the healthcare sector and expand its innovative therapeutic offerings.
